New technique developed by UAlberta researchers vastly improves precision of gene-editing technology.
Imagine a future where a guided biomachine put into your body seeks out defective gene sequences in each cell and edits in the correct information with precision accuracy.
It’s called gene editing, and University of Alberta researchers have just published a game-changing study that promises to bring the technology much closer to therapeutic reality.
“We’ve discovered a way to greatly improve the accuracy of gene-editing technology by replacing the natural guide molecule it uses with a synthetic one called a bridged nucleic acid, or BNA,” said Basil Hubbard, Canada Research Chair in Molecular Therapeutics and an assistant professor in the U of A’s Department of Pharmacology, who led the study.
He and his team have filed a patent on their discovery and are hoping to partner with the pharmaceutical industry to incorporate it into a therapeutic.
Interest in gene-editing technology has been rapidly rising since the discovery of CRISPR/Cas9. This system is naturally present in bacteria, which use it for protection against their natural predators, called bacteriophages.
“It allows bacteria to store information about previous infections and then use it to seek out and destroy the DNA of new invaders by cutting it,” explained Hubbard.
“What researchers have realized is that this system can be programmed to cut a specific DNA sequence in a human cell also, allowing us to edit our genes. One of the main issues, however, is that the system is not perfectly specific—sometimes it cuts a similar but incorrect gene.”
Using its natural RNA guide molecule, the Cas9 system is quite accurate, only making a mistake about one per cent of the time, he noted.
“However, given that there are trillions of cells in the human body, even one percentage off is quite significant, especially because gene editing is permanent. One wrong cut and a patient could end up with a serious condition like cancer.”
The new BNA guide molecule that Hubbard and his team—which includes PhD student Christopher Cromwell, who is first author on the study—developed was shown to be much more stable and stringent in its quest for finding the right DNA to cut.
“Our research shows that the use of bridged nucleic acids to guide Cas9 can improve its specificity by over 10,000 times in certain instances—a dramatic improvement,” said Hubbard.
Though gene-editing technology still has several hurdles to overcome, including the challenge of how to deliver it effectively into the human body, it may someday be used to treat a wide variety of genetic diseases, from muscular dystrophy to hemophilia and various cancers.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- CRISPR gene editing of brain cells might prevent Alzheimer's diseaseon November 26, 2020 at 12:11 pm
CRISPR gene editing could be used to introduce a rare gene variant that greatly reduces the risk of Alzheimer's, but it has only been tried in a dish so far ...
- Existing guidance appropriate for gene editing assessment, says EFSAon November 25, 2020 at 3:41 am
Genome editing does not pose any additional hazards compared to conventional breeding or other genetic modification methods, meaning that existing guidance is adequate for their assessment, the ...
- ChristianaCare Gene Editing Institute gets $1M grant to advance CRISPR workon November 24, 2020 at 2:40 am
The Lisa Dean Moseley Foundation has awarded a $1 million grant to scientists at ChristianaCare’s Gene Editing Institute to advance a novel gene therapy for sickle cell disease.
- Potential breakthrough for cystic fibrosis as Moscow scientists use gene-editing to correct part of mutation that causes diseaseon November 24, 2020 at 2:13 am
Scientists at Moscow's Bochkov Medical Genetic Research Center have successfully corrected a mutation of the CFTR gene, which causes cystic fibrosis. Using genetic editing, they replaced the parts of ...
- Researchers tackle sickle cell disease with CRISPR-based gene editingon November 23, 2020 at 5:23 am
Scientists at ChristianaCare's Gene Editing Institute have received a $1 million grant from the Lisa Dean Moseley Foundation to develop a novel gene therapy for inherited blood disorders including ...
- CRISPR-Based Gene Editing Approach Destroys Cancer Cells, Boost Survival From Some Cancers By 80 Percenton November 23, 2020 at 5:06 am
A revolutionary CRISPR-based gene therapy has shown impressive results in cell and mouse models, according to a study published in Science Advances. After ...
- CRISPR gene editing can be used to crush canceron November 21, 2020 at 10:34 am
Scientists have developed a new system using the CRISPR genome-editing system to attack and kill cancer cells. The system targets cancel cells directly and, like “scissors,” cuts their DNA ...
- Is Gene Editing Already Leaving CRISPR Therapeutics Behind?on November 21, 2020 at 8:33 am
Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever.
- Europe Gene Editing Market Revenue to Surpass USD 2.6 Billion by 2026on November 20, 2020 at 10:02 am
According to this report, the Europe gene editing market was valued at USD 1 billion in 2019 and is further projected to record a valuation of USD 2.6 billion by 2026 while depicting a growth rate of ...
via Bing News